Working… Menu
Trial record 3 of 3 for:    F-627 | Phase 3

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03252431
Recruitment Status : Completed
First Posted : August 17, 2017
Last Update Posted : July 17, 2020
Information provided by (Responsible Party):
Generon (Shanghai) Corporation Ltd.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : September 25, 2019
Actual Study Completion Date : March 5, 2020
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 January 4, 2021
(Canceled on January 7, 2021)
February 16, 2021
(Canceled on February 16, 2021)